Jaypicra 50mg (Pirtobrutinib Tablet) 50MG

JAYPICRA 50MG contains pirtobrutinib, a prescription tablet used for certain blood cancer treatments. It belongs to the BTK inhibitor class and is taken orally. This medication helps manage conditions where targeted therapy is required. Store below 25°C to maintain potency.

Strength

50MG

Pack Size

30S

Storage

Below 25°C

Manufacturer / TM Owner

Eli Lilly and Company

Select Quantity

Pack/s

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

First Name

Last Name

Phone

Delivery Country

Delivery PostCode/Zipcode

Select Your Profile

I have read and agree to the terms & conditions, including the privacy policy, return policy, and usage terms as applicable to this request.

Indications & Clinical Uses

Pirtobrutinib 50MG tablets are prescribed to treat specific types of blood cancers, including mantle cell lymphoma and chronic lymphocytic leukemia. It works by targeting abnormal B-cells to slow disease progression. Patients often use it when other treatments have not been effective. Always follow a healthcare provider’s guidance for appropriate use.

Side Effects

Common effects of pirtobrutinib include mild fatigue, digestive discomfort, and occasional dizziness. Some users report changes in appetite or mild headaches during early treatment. These effects are typically temporary and vary by individual. Staying hydrated and resting can help manage them.

Precautions & Warnings

Keep pirtobrutinib tablets in their original packaging and store below 25°C away from moisture and light. Handle with clean, dry hands to avoid contamination. Do not crush or split tablets unless advised by a healthcare professional. Keep out of reach of children and pets.

Avoid Interactions

Pirtobrutinib may interact with certain medications, including strong CYP3A inhibitors or inducers, which can affect its effectiveness. Avoid grapefruit products while taking this tablet, as they may alter drug levels. Always inform your doctor about all prescription, over-the-counter, and herbal products you use.

Frequently Asked Questions

Pirtobrutinib 50MG is used to treat certain blood cancers like mantle cell lymphoma and chronic lymphocytic leukemia.

Store pirtobrutinib tablets below 25°C in their original packaging, away from moisture and light.

Consult your doctor before combining pirtobrutinib with other drugs, as interactions may occur.

Common effects include fatigue, digestive discomfort, and mild headaches.

Pregnant or breastfeeding individuals should discuss risks with a healthcare provider before use.

Editorial & Trust Signals

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical wholesaler & exporter

Last updated: 17 Jun 2026

References

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.